MICA在NK细胞杀伤胰腺癌中的作用以及吉西他滨对胰腺癌细胞MICA蛋白脱落的影响
|
摘要
目的
探讨MICA及NK细胞活化性受体NKG2D在胰腺癌表达和临床意义
方法
RT-PCR技术检测10例胰腺癌、6例慢性胰腺炎和6例正常胰腺组织中MICA mRNA水平。免疫组化技术检测64例胰腺癌、13例慢性胰腺炎和11例正常胰腺组织中MICA的表达。ELISA和流式细胞术分别检测53例胰腺癌,7例慢性胰腺炎和20例健康志愿者血清中可溶性MICA (sMICA)水平和外周血中NK细胞受体NKG2D的表达。
结果
1.胰腺癌组织MICA mRNA表达水平显著高于慢性胰腺炎和正常胰腺组织(P<0.01)。
2.免疫组化显示胰腺癌组织中MICA阳性表达率为89.1%,显著高于慢性胰腺炎和正常胰腺组织(P<0.01)。MICA表达强度与胰腺癌分化程度、远处转移和临床分期密切相关(P=0.042,0.028,0.003)；MICA高表达的胰腺癌患者预后较好(P=0.019)。
3.胰腺癌患者血清sMICA水平显著高于健康志愿者和慢性胰腺炎患者(P<0.01),Ⅲ／Ⅳ期胰腺癌患者血清sMICA水平高于Ⅰ／Ⅱ期患者(P<0.01),有远处转移的胰腺癌患者血清sMICA水平较无转移患者明显增高(P<0.01)。
4.sMICA阳性胰腺癌患者外周血中NK细胞受体NKG2D的表达强度明显低于健康志愿者、慢性胰腺炎患者和sMICA阴性胰腺癌患者(P<0.01)。胰腺癌患者外周血中NK细胞受体NKG2D表达强度与血清sMICA水平呈显著负相关(P<0.01)
5.胰腺癌根治性切除可以下调患者血清sMICA水平和上调NK细胞受体NKG2D的表达。
结论
MICA作为免疫监视分子在早期胰腺癌组织中广泛表达,随着胰腺癌进展,MICA从胰腺癌细胞表面脱落形成sMICA,血清中sMICA含量增高可能导致了NK细胞受体NKG2D表达的下调。胰腺癌根治性切除可以下调患者血清sMICA水平和上调NK细胞受体NKG2D的表达。
目的
探讨MICA在NK细胞杀伤人胰腺癌PANC-1细胞中的作用
方法
应用NK细胞分选试剂盒从外周血中负向分选高纯度NK细胞用于实验。体外培养人胰腺癌PANC-1细胞和人NK细胞,应用抗体封闭法,观察NKG2D与膜型MICA识别在NK细胞杀伤PANC-1细胞中的作用。将正常NK细胞在含有sMICA阳性胰腺癌患者血清的培基中培养,观察NK细胞受体NKG2D的表达以及NK细胞对PANC-1细胞的杀伤作用。
结果
1.经MICA或NKG2D抗体封闭后,NK细胞的杀瘤活性较封闭前显著减弱(P<0.01)
2.胰腺癌患者血清中的sMICA可以下调NK细胞受体NKG2D的表达,并降低NK细胞对PANC-1细胞的杀伤活性。
结论
NKG2D与膜型MICA识别在NK细胞杀伤人胰腺癌PANC-1细胞中起重要作用。sMICA是造成胰腺癌免疫逃逸的重要分子机制之一。
目的
探讨ADAM10在PANC-1细胞MICA蛋白脱落过程中的作用,观察吉西他滨对MICA蛋白脱落的影响并探讨可能的作用机制。
方法
免疫组化检测64例胰腺癌和11例正常胰腺组织ADAM10的表达情况。通过化学合成的小分子干扰RNA(siRNA)下调PANC-1细胞ADAM10表达后,流式细胞术和ELISA分别检测细胞表面MICA的表达强度和细胞上清中sMICA的含量。采用MTT法检测不同浓度吉西他滨对PANC-1细胞增殖的影响。选择浓度为5ng/ml的吉西他滨作用PANC-1细胞24小时,RT-PCR和Western blot检测细胞中ADAM10 mRNA和蛋白表达水平,同时用RT-PCR、流式细胞术和ELISA分别检测MICA mRNA、细胞表面MICA的表达强度和细胞上清中sMICA的含量。先用ADAM10 siRNA或阴性对照siRNA转染PANC-1细胞,转染24小时后,再加入吉西他滨(对照组加等体积培基)继续培养24小时,流式细胞术和ELISA分别检测细胞表面MICA的表达强度和细胞上清中sMICA的含量。
结果
1.ADAM10在胰腺癌组织中阳性表达率(87.5%)显著高于正常胰腺组织(P<0.01)。
2.下调ADAM10表达后,PANC-1细胞表面MICA表达增强,而细胞上清液中sMICA的含量减少(P<0.01)。
3.当培基中浓度小于7ng／ml时,吉西他滨在24小时内对PANC-1细胞增殖无明显影响(P>0.05)。
4.吉西他滨显著下调PANC-1细胞ADAM10mRNA和蛋白的表达水平(P<0.01)。
5.吉西他滨(5ng／ml)作用PANC-1细胞24小时后,细胞表面MICA表达增强,细胞上清液中sMICA的含量减少(P<0.01)。吉西他滨对PANC-1细胞MICA mRNA表达无明显影响。
6.siRNA下调ADAM 10表达后,吉西他滨对PANC-1细胞表面MICA蛋白的表达和上清液中sMICA的含量无明显影响(P>0.05)。
结论
ADAM 10在PANC-1细胞MICA蛋白脱落过程中具有重要作用。吉西他滨可以抑制PANC-1细胞MICA蛋白的脱落,其机制可能与下调ADAM 10的表达有关。
Objective:To investigate the clinical significance of MICA and NKG2D receptor on NK cells in pancreatic cancer.
Methods:MICA mRNA in 10 pancreatic cancer tissues,6 chronic pancreatitis tissues and 6 normal tissues of pancreas was determined by RT-PCR analysis.Expression of MICA in 64 pancreatic cancer tissues, 13 chronic pancreatitis samples and 11 normal tissues of pancreas was examined by immunohistochemistry. The serum levels of sMICA and NKG2D expression on NK cells of 53 pancreatic cancer patients,7 patients with chronic pancreatitis and 20 healthy volunteers was assessed by ELISA and Flow cytometry analysis.
Results:There was a significant increase in MICA mRNA levels in the pancreatic cancer samples compared with the chronic pancreatitis and normal tissues of pancreas(P<0.01).The positive rate of MICA immunostaining in pancreatic cancer tissues was 89.1%,whereas fewer was expressed in inflammatory and normal pancreatic tissues(P<0.01). Significant difference was noted between the MICA expression with respect to the histological grade(P=0.042),distant metastasis(P=0.028) and TNM stages (P=0.003).MICA expression was found to be a prognostic factor in resected pancreatic cancer (P=0.019).The serum levels of sMICA were frequently elevated in patients with pancreatic cancer (P<0.01).The level of sMICA was significantly higher inⅢ/Ⅳstage pancreatic cancer patients than that in I/II stage patients (P<0.01).Notably, our data also showed that sMICA levels correlated significantly with the presence of metastasis(P<0.01).NKG2D expression on NK cells from sMICA-positive pancreatic cancer patients was markedly reduced compared to that from sMICA-negative pancreatic cancer patients, chronic pancreatitis patients or healthy volunteers (P<0.01).Significant inverse correlation between NKG2D expression and levels of sMICA was observed in pancreatic cancer patients (r=-0.499,P<0.01).The successful radical resection of tumor significantly decreased the serum levels of sMICA and increased the NKG2D expression on NK cells.
Conclusions:MICA is induced and expressed widely in the early stage of pancreatic cancer.With the progression of pancreatic cancer, MICA can be released into the bloodstream or tissue culture medium as sMICA.The elevation of sMICA may be associated with down-regulated NKG2D expression on NK cells.The successful radical resection of tumor significantly decreased the serum levels of sMICA and increased the NKG2D expression on NK cells.
Objective:To investigate the role of MICA on anti-human pancreatic cancer cell line PANC-1 mediated by NK cells.
Methods:NK cells were purified by negative depletion using NK cell isolation kit by Vario MACS system.Studyed the reaction between MICA and NKG2D by purified-antibody blockade.Cultured NK cells from healthy donors with sMICA-positive serum for 24 h and assessed the NKG2D expression and Cytotoxicity of NK cells to PANC-1 cells.
Results:
1.Cytotoxicity of NK cells to PANC-1 cells was decreased because of NKG2D or MICA antibody blockade(P<0.01)
2.The expression of NKG2D was decreased after NK cells cultured with sMICA-positive serum.NK cells pre-treated with sMICA-positive serum were not capable of efficiently killing PANC-1 cells.
Conclusions:MICA-NKG2D play a critical role in cytotoxicity of NK cells to PANC-1 cells.sMICA reduce the expression of NKG2D,and impaire NK cell-mediated imnune surveillance in pancreatic cancer.
Part 3 ADAM10 is involved in MICA shedding and effects of gemcitabine on MICA protein ectodomain shedding in PANC-1 cells
Objective:To investigate the role of ADAM 10 on MICA protein ectodomain shedding and observe whether gemcitabine affect MICA protein shedding from PANC-1 cells.
Methods:
1.Expression of ADAM 10 in 64 pancreatic cancer tissues and 11 normal pancreas tissues was examined by immunohistochemistry.
2. PANC-1 cells were transfected with ADAM10 siRNA or control siRNA for 48 h. The expression of membrane-bound MICA was evaluated by flow cytometry,and sMICA production in the culture supernatant was evaluated by ELISA.
3.The cytotoxicity of gemcitabine to PANC-1 cells was evaluated by MTT.
4.PANC-1 cells were treated with a nontoxic dose of 5ng/ml gemcitabine for 24 h,and their expression of ADAM 10 were evaluated by RT-PCR and Western blot.The expression of membrane-bound MICA and MICA mRNA were evaluated by flow cytometry and RT-PCR, respectively. At the same time,24h culture supernatants were subjected to the analysis of sMICA levels by ELISA.
5.PANC-1 cells were transfected with ADAM10 siRNA or control siRNA for 24 h and further cultured with 5ng/ml gemcitabine (equal culture medium for control)for 24 h.The expression of membrane-bound MICA was evaluated by flow cytometry,and sMICA production in the culture supernatants was evaluated by ELISA。
Results:
1.The positive rate of ADAM 10 immunostaining in pancreatic cancer tissues(87.5%)was significant higher than in normal tissues of pancreas(P<0.01)
2.Knockdown of ADAM10 for PANC-1 cells clearly upregulated MICA expression on their cellular surface and downregulated sMICA levels in their culture supernatants(P<0.01)
3.When the concentration of gemcitabine was lower than 7ng/ml, gemcitabine maked little effect on the growth of PANC-1 cells in 24h.
4.Gemcitabine suppresses ADAM10 expression in PANC-1 cells (P<0.01)
5.Gemcitabine(5ng/ml)treatment led to an increase in membrane-bound MICA expression and a decrease in sMICA production in PANC-1 cells(P<0.01).The mRNA levels of MICA did not change after PANC-1 cells exposure to gemcitabine(P>0.05)
6.PANC-1 cells were transfected with ADAM10 siRNA and then treated with gemcitabine.Neither upregulation of surface MICA nor downregulation of soluble MICA levels was observed.
Conclusions:ADAM 10 is involved in MICA shedding of PANC-1 cells.Gemcitabine inhibits MICA ectodomain shedding through suppression of ADAM10.
探讨MICA及NK细胞活化性受体NKG2D在胰腺癌表达和临床意义
方法
RT-PCR技术检测10例胰腺癌、6例慢性胰腺炎和6例正常胰腺组织中MICA mRNA水平。免疫组化技术检测64例胰腺癌、13例慢性胰腺炎和11例正常胰腺组织中MICA的表达。ELISA和流式细胞术分别检测53例胰腺癌,7例慢性胰腺炎和20例健康志愿者血清中可溶性MICA (sMICA)水平和外周血中NK细胞受体NKG2D的表达。
结果
1.胰腺癌组织MICA mRNA表达水平显著高于慢性胰腺炎和正常胰腺组织(P<0.01)。
2.免疫组化显示胰腺癌组织中MICA阳性表达率为89.1%,显著高于慢性胰腺炎和正常胰腺组织(P<0.01)。MICA表达强度与胰腺癌分化程度、远处转移和临床分期密切相关(P=0.042,0.028,0.003)；MICA高表达的胰腺癌患者预后较好(P=0.019)。
3.胰腺癌患者血清sMICA水平显著高于健康志愿者和慢性胰腺炎患者(P<0.01),Ⅲ／Ⅳ期胰腺癌患者血清sMICA水平高于Ⅰ／Ⅱ期患者(P<0.01),有远处转移的胰腺癌患者血清sMICA水平较无转移患者明显增高(P<0.01)。
4.sMICA阳性胰腺癌患者外周血中NK细胞受体NKG2D的表达强度明显低于健康志愿者、慢性胰腺炎患者和sMICA阴性胰腺癌患者(P<0.01)。胰腺癌患者外周血中NK细胞受体NKG2D表达强度与血清sMICA水平呈显著负相关(P<0.01)
5.胰腺癌根治性切除可以下调患者血清sMICA水平和上调NK细胞受体NKG2D的表达。
结论
MICA作为免疫监视分子在早期胰腺癌组织中广泛表达,随着胰腺癌进展,MICA从胰腺癌细胞表面脱落形成sMICA,血清中sMICA含量增高可能导致了NK细胞受体NKG2D表达的下调。胰腺癌根治性切除可以下调患者血清sMICA水平和上调NK细胞受体NKG2D的表达。
目的
探讨MICA在NK细胞杀伤人胰腺癌PANC-1细胞中的作用
方法
应用NK细胞分选试剂盒从外周血中负向分选高纯度NK细胞用于实验。体外培养人胰腺癌PANC-1细胞和人NK细胞,应用抗体封闭法,观察NKG2D与膜型MICA识别在NK细胞杀伤PANC-1细胞中的作用。将正常NK细胞在含有sMICA阳性胰腺癌患者血清的培基中培养,观察NK细胞受体NKG2D的表达以及NK细胞对PANC-1细胞的杀伤作用。
结果
1.经MICA或NKG2D抗体封闭后,NK细胞的杀瘤活性较封闭前显著减弱(P<0.01)
2.胰腺癌患者血清中的sMICA可以下调NK细胞受体NKG2D的表达,并降低NK细胞对PANC-1细胞的杀伤活性。
结论
NKG2D与膜型MICA识别在NK细胞杀伤人胰腺癌PANC-1细胞中起重要作用。sMICA是造成胰腺癌免疫逃逸的重要分子机制之一。
目的
探讨ADAM10在PANC-1细胞MICA蛋白脱落过程中的作用,观察吉西他滨对MICA蛋白脱落的影响并探讨可能的作用机制。
方法
免疫组化检测64例胰腺癌和11例正常胰腺组织ADAM10的表达情况。通过化学合成的小分子干扰RNA(siRNA)下调PANC-1细胞ADAM10表达后,流式细胞术和ELISA分别检测细胞表面MICA的表达强度和细胞上清中sMICA的含量。采用MTT法检测不同浓度吉西他滨对PANC-1细胞增殖的影响。选择浓度为5ng/ml的吉西他滨作用PANC-1细胞24小时,RT-PCR和Western blot检测细胞中ADAM10 mRNA和蛋白表达水平,同时用RT-PCR、流式细胞术和ELISA分别检测MICA mRNA、细胞表面MICA的表达强度和细胞上清中sMICA的含量。先用ADAM10 siRNA或阴性对照siRNA转染PANC-1细胞,转染24小时后,再加入吉西他滨(对照组加等体积培基)继续培养24小时,流式细胞术和ELISA分别检测细胞表面MICA的表达强度和细胞上清中sMICA的含量。
结果
1.ADAM10在胰腺癌组织中阳性表达率(87.5%)显著高于正常胰腺组织(P<0.01)。
2.下调ADAM10表达后,PANC-1细胞表面MICA表达增强,而细胞上清液中sMICA的含量减少(P<0.01)。
3.当培基中浓度小于7ng／ml时,吉西他滨在24小时内对PANC-1细胞增殖无明显影响(P>0.05)。
4.吉西他滨显著下调PANC-1细胞ADAM10mRNA和蛋白的表达水平(P<0.01)。
5.吉西他滨(5ng／ml)作用PANC-1细胞24小时后,细胞表面MICA表达增强,细胞上清液中sMICA的含量减少(P<0.01)。吉西他滨对PANC-1细胞MICA mRNA表达无明显影响。
6.siRNA下调ADAM 10表达后,吉西他滨对PANC-1细胞表面MICA蛋白的表达和上清液中sMICA的含量无明显影响(P>0.05)。
结论
ADAM 10在PANC-1细胞MICA蛋白脱落过程中具有重要作用。吉西他滨可以抑制PANC-1细胞MICA蛋白的脱落,其机制可能与下调ADAM 10的表达有关。
Objective:To investigate the clinical significance of MICA and NKG2D receptor on NK cells in pancreatic cancer.
Methods:MICA mRNA in 10 pancreatic cancer tissues,6 chronic pancreatitis tissues and 6 normal tissues of pancreas was determined by RT-PCR analysis.Expression of MICA in 64 pancreatic cancer tissues, 13 chronic pancreatitis samples and 11 normal tissues of pancreas was examined by immunohistochemistry. The serum levels of sMICA and NKG2D expression on NK cells of 53 pancreatic cancer patients,7 patients with chronic pancreatitis and 20 healthy volunteers was assessed by ELISA and Flow cytometry analysis.
Results:There was a significant increase in MICA mRNA levels in the pancreatic cancer samples compared with the chronic pancreatitis and normal tissues of pancreas(P<0.01).The positive rate of MICA immunostaining in pancreatic cancer tissues was 89.1%,whereas fewer was expressed in inflammatory and normal pancreatic tissues(P<0.01). Significant difference was noted between the MICA expression with respect to the histological grade(P=0.042),distant metastasis(P=0.028) and TNM stages (P=0.003).MICA expression was found to be a prognostic factor in resected pancreatic cancer (P=0.019).The serum levels of sMICA were frequently elevated in patients with pancreatic cancer (P<0.01).The level of sMICA was significantly higher inⅢ/Ⅳstage pancreatic cancer patients than that in I/II stage patients (P<0.01).Notably, our data also showed that sMICA levels correlated significantly with the presence of metastasis(P<0.01).NKG2D expression on NK cells from sMICA-positive pancreatic cancer patients was markedly reduced compared to that from sMICA-negative pancreatic cancer patients, chronic pancreatitis patients or healthy volunteers (P<0.01).Significant inverse correlation between NKG2D expression and levels of sMICA was observed in pancreatic cancer patients (r=-0.499,P<0.01).The successful radical resection of tumor significantly decreased the serum levels of sMICA and increased the NKG2D expression on NK cells.
Conclusions:MICA is induced and expressed widely in the early stage of pancreatic cancer.With the progression of pancreatic cancer, MICA can be released into the bloodstream or tissue culture medium as sMICA.The elevation of sMICA may be associated with down-regulated NKG2D expression on NK cells.The successful radical resection of tumor significantly decreased the serum levels of sMICA and increased the NKG2D expression on NK cells.
Objective:To investigate the role of MICA on anti-human pancreatic cancer cell line PANC-1 mediated by NK cells.
Methods:NK cells were purified by negative depletion using NK cell isolation kit by Vario MACS system.Studyed the reaction between MICA and NKG2D by purified-antibody blockade.Cultured NK cells from healthy donors with sMICA-positive serum for 24 h and assessed the NKG2D expression and Cytotoxicity of NK cells to PANC-1 cells.
Results:
1.Cytotoxicity of NK cells to PANC-1 cells was decreased because of NKG2D or MICA antibody blockade(P<0.01)
2.The expression of NKG2D was decreased after NK cells cultured with sMICA-positive serum.NK cells pre-treated with sMICA-positive serum were not capable of efficiently killing PANC-1 cells.
Conclusions:MICA-NKG2D play a critical role in cytotoxicity of NK cells to PANC-1 cells.sMICA reduce the expression of NKG2D,and impaire NK cell-mediated imnune surveillance in pancreatic cancer.
Part 3 ADAM10 is involved in MICA shedding and effects of gemcitabine on MICA protein ectodomain shedding in PANC-1 cells
Objective:To investigate the role of ADAM 10 on MICA protein ectodomain shedding and observe whether gemcitabine affect MICA protein shedding from PANC-1 cells.
Methods:
1.Expression of ADAM 10 in 64 pancreatic cancer tissues and 11 normal pancreas tissues was examined by immunohistochemistry.
2. PANC-1 cells were transfected with ADAM10 siRNA or control siRNA for 48 h. The expression of membrane-bound MICA was evaluated by flow cytometry,and sMICA production in the culture supernatant was evaluated by ELISA.
3.The cytotoxicity of gemcitabine to PANC-1 cells was evaluated by MTT.
4.PANC-1 cells were treated with a nontoxic dose of 5ng/ml gemcitabine for 24 h,and their expression of ADAM 10 were evaluated by RT-PCR and Western blot.The expression of membrane-bound MICA and MICA mRNA were evaluated by flow cytometry and RT-PCR, respectively. At the same time,24h culture supernatants were subjected to the analysis of sMICA levels by ELISA.
5.PANC-1 cells were transfected with ADAM10 siRNA or control siRNA for 24 h and further cultured with 5ng/ml gemcitabine (equal culture medium for control)for 24 h.The expression of membrane-bound MICA was evaluated by flow cytometry,and sMICA production in the culture supernatants was evaluated by ELISA。
Results:
1.The positive rate of ADAM 10 immunostaining in pancreatic cancer tissues(87.5%)was significant higher than in normal tissues of pancreas(P<0.01)
2.Knockdown of ADAM10 for PANC-1 cells clearly upregulated MICA expression on their cellular surface and downregulated sMICA levels in their culture supernatants(P<0.01)
3.When the concentration of gemcitabine was lower than 7ng/ml, gemcitabine maked little effect on the growth of PANC-1 cells in 24h.
4.Gemcitabine suppresses ADAM10 expression in PANC-1 cells (P<0.01)
5.Gemcitabine(5ng/ml)treatment led to an increase in membrane-bound MICA expression and a decrease in sMICA production in PANC-1 cells(P<0.01).The mRNA levels of MICA did not change after PANC-1 cells exposure to gemcitabine(P>0.05)
6.PANC-1 cells were transfected with ADAM10 siRNA and then treated with gemcitabine.Neither upregulation of surface MICA nor downregulation of soluble MICA levels was observed.
Conclusions:ADAM 10 is involved in MICA shedding of PANC-1 cells.Gemcitabine inhibits MICA ectodomain shedding through suppression of ADAM10.
引文
[1]Michaud DS.Epidemiology of pancreatic cancer. Minerva Chir,2004,59(2):99-111.
[2]Lowenfels AB,Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol,2004,34(5):238-244.
[3]Jemal A, Siegel R, Ward E, Cancer statistics,2009. CA Cancer J Clin, 2009,59(4):225-249.
[4]Kleeff J, Michalski C,Friess H,Pancreatic cancer:from bench to 5-year survival. Pancreas,2006,33(2):111-118.
[5]Brasiuniene B,Juozaityte E.The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina (Kaunas), 2007,43(9):716-725.
[6]Ishigami S,Natsugoe S,Tokuda K,et al.Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer,2000,8(3):577-583.
[7]Coca S,Perez-Piqueras J, Martinez D, et al.The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 1997,9(12):2320-2328.
[8]Takanami I,Takeuchi K, Giga M.The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg,2001,21(6):1058-1063.
[9]Smyth MJ, Cretney E, Kelly JM, Activation of NK cell cytotoxicity. Mol Immunol,2005,42(4):501-510.
[10]陈慰峰.医学免疫学.人民卫生出版社.
[11]Cerwenka A, Lanier LL.NKG2D ligands:unconventional MHC class I like molecules exploited by viruses and cancer. Tissue Antigen,2003,61(5):335-343.
[12]Zhang C, Zhang J, Wei H, et al.Immunoreceptor and its ligands [J].Int Immunopharmacol,2005,5(7-8):1099-1111.
[13]Bahram S,Bresnahan M, Geraghty DE,et al.A second lineage of mammalian major histocompatibility complex class I genes.Proc Natl Acad Sci U S A,
1994,91(14):6259-6263.
[14]Ostberg JR, Dayanc BE, Yuan M, et al.Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.J Leukoc Biol,2007,82(5):1322-1331.
[15]Raulet DH.Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol,2003,3(10):781-790.
[16]Molinero LL,Fuertes MB,Rabinovich GA,et al.Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.J Leukoc Biol, 2002,71(5):791-797.
[17]Watson NF,et al.Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.Int J Cancer,2006,18(6):1445-1452.
[18]Madjd Z,Spendlove I,Moss R,et al.Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun,2007,7(6):17-19.
[19]Clayton A,Tabi Z.Exosomes and the MICA-NKG2D system in cancer.Blood Cells Mol Dis,2005,34(3):206-213.
[20]Fuertes MB,Girart MV, Molinero LL,et al.Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol,2008,180(7): 4606-4014.
[21]Stastny P.Introduction:MICA/MICB in innate immunity, adaptive immunity, autoimmunity,cancer,and in the immune response to transplants.Hum Immunol, 2006,67(3):141-144.
[22]Groh V,Rhinehart R,Secrist H,et al.Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.Proc. Natl.Acad. Sci.U. S.A,1999,96:6879-6884.
[23]Vetter CS,Groh V, thor Straten P, et al.Expression of stress-induced MHC class I related chain molecules on human melanoma.J.Invest.Dermatol,2002,118:600-605.
[24]Jinushi M,Takehara T,Tatsumi T, et al.Expression and role of MICA and MICB
in human hepatocellular carcinomas and their regulation by retinoic acid.Int.J. Cancer,2003,104:354-361.
[25]Bauer S,Groh V,Wu J,et al.Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.Science,1999,285(5428):727-729.
[26]Pardoll DM.Immunology.Stress,NK receptors, and immune surveillance.Science, 2001,294(5542):534-536.
[27]Diefenbach A, Jensen ER, Jamieson AM,et al.Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature,2001,413(6852):165-171.
[28]Groh V,Wu J,Yee C,et a 1.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.Nature,2002,419:734-738.
[29]Holdenrieder S,Stieber P, Peterfi A, et al.Soluble MICA in malignant diseases. Int J Cancer,2006,118:684-687
[30]Kaiser BK,Yim D,Chow IT,et al.Disulphideisomerase-enabled shedding of tumour-associated NKG2D ligands.Nature,2007,447:482-486.
[31]Salih HR,Rammensee HGSteinle A,Down-regulation of MICA on human tumors by proteolytic shedding.J Immunol,2002,169(8):4098-4102.
[32]Palmisano R,Itoh Y.Analysis of MMP-dependent cell migration and invasion. Methods Mol Biol,2010,622:379-392.
[33]Blobel CP. ADAMs:key components in EGFR signalling and development. Nat Rev Mol Cell Biol,2005,6(1):32-43.
[34]Reiss K,Ludwig A.Breaking up the tie:disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther,2006, 111:985-1006.
[35]White JM.ADAMs:modulators of cell-cell and cell-matrix interactions.Curr Opin Cell Biol,2003,15(5):598-606.
[36]Waldhauer I,Goehlsdorf D,Gieseke F, et al.Tumor-Associated MICA Is Shed by ADAM Proteases.Cancer Res,2008,68(15):6368-6376.
[37]Lake RA,Robinson BW.Immunotherapy and chemotherapy--a practical partner-ship.Nat Rev Cancer,2005,5(5):397-405.
[38]Weiskirch LM.Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice
engaged in tumor eradication following low-dose melphalan therapy.Cancer Immunol Immunother,1994,38(4):215-224.
[39]Yuan L,Kobayashi M, Kuramitsu Y,et al.Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor beta in rats bearing KDH-8 hepatoma cells.Cancer Immunol Immunother,1997,45(2):71-76.
[40]Machiels JP, Reilly RT, Emens LA, et al.Cyclophosphamide,doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.Cancer Res,2001,61(9):3689-3697.
[41]Merritt RE, Mahtabifard A, Yamada RE, et al.Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.J Thorac Cardiovasc Surg,2003,126(5):1609-1617.
[42]Peter Ujhazy, Gintaras Zaleskis, Enrico Mihich.Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother,2003,52(7):463-472.
[43]Jinushi M,Takehara T,Tatsumi T,et al.Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.Int Jcancer,2003,104(3):354-361.
[44]meanu S,Bitzer M,Lauer UM,et al.Natural killer cell mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histonedeacetylase inhibitor sodium valproate.Cancer Res,2005,65(14):6321-6329.
[45]Gasser S,Orsulic S,Brown EJ,et al.The DNA damage pathway regulates innate immune system 1 igands of the NKG2D receptor.Nature,2005,436 (7054):1186-1190.
[46]Suzuki E, Sun J, Kapoor V, et al.Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.Cancer Biol Ther,2007,6(6):880-885
[47]Li K, Mandai M, Hamanishi J, Matsumura N.et al.Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer:high expression of ULBP2 is an indicator of poor prognosis.Cancer Immunol Immunother
2009,58(5):641-652.
[48]Groh V, A.Steinle, S.Bauer, et al.Recognition of stress-induced MHC molecules by intestinal epithelial T cells.Science,1998,279:1737-1740.
[49]Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells,fibroblasts,keratinocytes,and monocytes.Hum.Immunol,1999, 60:323-330.
[50]Yamamoto K, Fujiyama Y, Andoh A, et al.Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biophys Acta,2001,1526(1):10-12.
[51]Cerwenka A,Lanier LL.NKG2D ligands:unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens,2003,61:335-343
[52]Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K,Plymate SR. Prevalent expression of the immunostimulatoryMHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest,2004,114:560-568.
[53]Angela Marten, Marie von Lilienfeld-Toal,Markus W, et al.Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int. J.Cancer,2006,119:2359-2365.
[54]Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases.Int J Cancer,2006,118(3):684-687.
[55]Kohga K, Takehara T, Tatsumi T, et al.Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci,2008,99(8):1643-1649.
[56]Kim S,Iizuka K,Aguila HL, Weissman IL, et al.In vivo natural killer cell activities revealed by natural killer cell-deficient mice.Proc Natl Acad Sci U S A,2000,97(6):2731-2736.
[57]Pross HF,Lotzova E.Role of natural killer cells in cancer.Nat Immunol,1993,12(4-5):279-292.
[58]Aparicio-Pages MN,Verspaget HW, Pena AS,et al.Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract.J Clin Lab Immunol,1991,35(1):27-32.
[59]Cosman D,Mullberg J,Sutherland CL,et al.ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity,2001,14(2):123-133.
[60]Busche A, Goldmann T, Naumann U,et al.Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther,2006,17 (2):135-146.
[61]Friese MA, Platten M, Lutz SZ, et al.MICA/NKG2D-mediated immunogene therapy of experimental gliomas.Cancer Res,2003,63(24):8996-9006.
[62]Smyth MJ, Godfrey DI,Trapani JA.A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol,2001,2(4):293-299.
[63]Angela Marten,Marie von Lilienfeld-Toal,Markus W, et al.Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int.J. Cancer,2006,119:2359-2365.
[64]Doubrovina ES, Doubrovin MM, Vider E, et al.Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.J Immunol,2003,171:6891-6899.
[65]Shun-Yao Ko,Shu-Chun Lin, Yong-Kie Wong,et al.Increase of disintergin metalloprotease 10 (ADAM 10) expression in oral squamous cell carcinoma. Can-cer Letters.2007;245(1-2):33-43.
[66]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression. Cancer Sci,2007,98(5):621-628.
[67]Huovila AP, Turner AJ, Pelto-Huikko M,et al.Shedding light on ADAM metalloproteinases.Trends Biochem Sc,2005,30(7):413-422.
[68]Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response:implications for combination chemo-immunotherapy. Cancer Res,2002,62(8):2353-2358.
[69]Nowak AK, Lake RA,Marzo AL,et al.Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.J Immunol,2003,170(10):4905-4913.
[70]Le HK, Graham L,Cha E.Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.Int Immunopharmacol, 2009,9(7-8):900-909.
[71]Bang S,Kim HS,Choo YS,et al.Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas,2006,32(1):29-36.
[72]Hirooka Y, Itoh AKawashima H,et al.A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas,2009,38(3):69-74
[73]Correale P, Cusi MG, Tsang KY,et al.Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.J Clin Oncol,2005,23(35):8950-8958.
[74]Dudley ME, Wunderlich JR, Yang JC,et al.Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005,23(10):2346-2357.
[1]Bhram S,Bresnahan M,Geraghty DE,et al.A second lineage of mammnalian major histocompatibility complex class I genes.Proc Natl Acad Sci USA,1994,91 (14):6259-6263.
[2]Bhram S,Mizuki N,Inoko H,et al.Nucleotide sequence of the human MHC class I MICA gene.Immunogenetics,1996,44(1):80-81.
[3]Perez-Rodriguez M,Arguello JR,Fischer G,et al.Further polymorphism of the MICA gene.Eur J Immunogenet,2002,29(l):35-46.
[4]Li P,Morris DL,Willcox BE,Steinle A,Spies T,Strong RK.Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA.Nat Immunol,2001,2(5):443-451.
[5]Perez-Rodriguez M, Arguello JR, Fischer G,et al.Further polymorphism of the MICA gene.Eur J Immunogenet,2002,29(1):35-46.
[6]Fodil N, Laloux L,Wanner V,et al.Allelic repertoire of the human MHC class Ⅰ MICA gene.Immunogenetics,1996,44(5):351-357.
[7]Suemizu H,Radosavljevic M, Kimura M,et al.A basolateral sorting motif in the MICA cytoplasmic tail.Proc Natl Acad Sci U S A,2002,99(5):2971-2976.
[8]Lengyel CS,Willis LJ, Mann P,et al.Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity. J Biol Chem,2007,282(42):30658-30666.
[9]Petersdorf EW, Shuler KB,Longton GM,et al.Population study of allelic
diversity in the human MHC class I-related MIC-A gene.Immunogenetics,1999, 49(7-8):605-612.
[10]Katsuyama Y, Ota M,Ando H,et al.Sequencing based typing for genetic polymorphisms in exons,2,3 and 4 of the MICA gene.Tissue Antigens,1999,54 (2):178-184.
[11]龚卫娟,范丽安,杨珏琴,等.三个群体MICA基因外显子2、3和4的多态性研究.中华医学遗传学杂志,2002,19(4)：336-339.
[12]Ribas F.Olivera LA,Petzl-Erler ML,et al.Major histocompatib-ility complex class I chain-related gene A polymorphism and linkage disequilibrium with HLA-B alleles in Euro-Brazilians.Tissue Antigens,2008,72(6):532-538.
[13]Lucas D,Campillo JA,L6pez-Hernandez R, et al.Allelic diversity of MICA gene and MICA/HLA-B haplotypic variation in a population of the Murcia region in southeastern Spain.Hum Immunol,2008,69(10):655-660.
[14]Yabuki K, Ota M,Goto K, Kimura T,et al.Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative caucasian patients with ankylosing spondylitis.Hum Immunol,1999,60(1):83-86.
[15]肖翠英,张思仲,程璐,等.中国四个人群中MICA基因多态性研究.中华医学遗传学杂志,2000,17(6)：424-428.
[16]Lo SS,Lee YJ, Wu CW,et al.The increase of MICA gene A9 allele associated with gastric cancer and less schirrous change.Br J Cancer,2004,90(9):1809-13.
[17]Chung-Ji L,Yann-Jinn L,Hsin-Fu L,et al.The increase in the frequency of MICA gene A6 allele in oral squamous cell carcinoma. J Oral Pathol Med,2002,31(6): 323-328.
[18]Liu CJ,Lee YJ, Chang KW,et al.Polymorphism of the MICA gene and risk for oral submucous fibrosis.J Oral Pathol Med,2004,33(1):1-6.
[19]Tamaki S,Sanefuzi N, Ohgi K,et al.An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients.J Oral Pathol Med,2007,36(6):351-356.
[20]Tian W,Zeng XM, Li LX,et al.Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population.Immunogenetics,2006,58(2-3):113-121.
[21]Kennedy C, Naipal A, Gruis NA,et al.MICA gene polymorphism is not associated with an increased risk for skin cancer. J Invest Dermatol,2002,118(4): 686-691.
[22]Lavado-Valenzuela R,Benavides. M,Carabantes F, MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. Tissue Antigens,2009,74(1):46-49.
[23]Ostberg JR,Dayanc BE,Yuan M,et al.Enhancement of natural killer(NK) cell Cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.J Leukoc Biol,2007,82(5):1322-1331.
[24]Raulet DH.Roles of the NKG2D imunoreceptor and its ligands.Nat Rev Immunol,2003,3(10):781-790.
[25]Molinero LL,Fuertes MB,Rabinovich GA,et al.Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.J Leukoc Biol,2002,71(5):791-797.
[26]Hankey KQDrachenberg CB,Papadimitriou JC,et al.MIC expression in renal and pancreatic allografts.Transplantation,2002,73(2):304-306.
[27]Kato M,Kinukawa T,Hattori R,et al.Does MICA influence acute rejection in kidney transplantation.Clin Transpl,2006,389-393.
[28]Morales-Buenrostro LE,Rodrfguez-Romo R,de Leo C,et al.HLA and MICA antibodies:further evidence of their impact on graft loss two years after their detection.Clin Transpl,2006,207-218.
[29]Watson NF,Spendlove I,Madjd Z,et al.Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.Int J Cancer,2006,118(6):1445-1452.
[30]Clayton A,Tabi Z.Exosomes and the MICA-NKG2D system in cancer.Blood Cells Mol Dis,2005,34(3):206-213.
[31]Madjd Z,Spendlove I,Moss R,et al.Upregulat ion of MICA on high-grade invasive operable breast carcinoma.Cancer Immun,2007,7:17.
[32]Fuertes MB,Girart MV,Molinero LL,et al.Intracellular Retention of the NKG2D 1 igand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.J Immunol,2008, 180(7):4606-4614.
[33]Stastny P.Introduction:MICA/MICB in innate immunity,adaptive immunity, autoimmunity,cancer,and in the immune response to transplants.Hum Immunol,2006,67(3):141-144.
[34]Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer,2006,119(10):2359-2365.
[35]Groh V, et al.Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.Proc.Natl.Acad.Sci.U. S.A,1999,96:6879-6884.
[36]Jinushi M,Takehara T,Tatsumi T.et al.Autocrine/paracrineIL-15 that is required fortype I IFN-mediated dendritic eel l expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.J Immunol,2003,171(10): 5423-5429.
[37]Zhang C,Zhang J,Sun R,et al.Opposing effect of IFN-gamma and IFN-alpha on expression of NKG2 receptors:negative regulation of IFN-gamma on NK cells.Int Immunopharmacol,2005,5(6):1057-1067.
[38]Friese MA,Wischhusen J,Wick W,et al.RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response,inhibits glioma cell migration and invasiveness,and abrogates tumorigenicity in vivo.Cancer Res,2004,64(20):7596-7603.
[39]Eisele G,Wischhusen J,Mittelbronn M,et al.TGF-beta and metalloproteinases differenially suppress NKG2D ligand surface expression on malignant glioma cells Brain,2006,129(Pt 9):2416-25.
[40]Molinero LL,Fuertes MB,Girart Mv,et al.NF-K B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes.J Immunol,2004, 173(9):5583-5590.
[41]Jinushi M,Takehara T,Tatsumi T,et al.Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.Int Jcancer,2003,104(3):354-361.
[42]meanu S,Bitzer M,Lauer UM,et al.Natural killer cell mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histonedeacetylase inhibitor sodium valproate.Cancer Res.2005;65(14):6321-6329.
[43]Gasser S,Orsulic S,Brown EJ,et al.The DNA damage pathway regulates innate immune system 1 igands of the NKG2D receptor.Nature,2005;436 (7054):1186-1190.
[44]Zou Y,Bresnahan W,Taylor RT,et al.Effect of human cytomegalovirus on expression of MHC class I-related chains A.J Immunol,2005,174(5):3098-4004.
[45]Friese MA,Wischhusen J, Wick W,et al.RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness,and abrogates tumorigenicity in vivo.Cancer Res,2004,64(20):7596-7603.
[46]Bauer S,Groh V, Wu J,et al.Activation of NK cells and T cells by NKG2D,a receptor for stress-inducible MICA.Science,1999,285(5428):727-729.
[47]Pardoll DM.Immunology. Stress, NK receptors, and immune surveillance. Science,2001,294(5542):534-536.
[48]Diefenbach A, Tomasello E, Lucas M,et al.Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D.Nat Immunol,2002,3(12):1142-1149.
[49]Long EO. Versatile signaling through NKG2D.Nat Immunol,2002,3(12): 1119-1120
[50]Wu J, Song Y, Bakker AB,et al.An activating immunoreceptor complex formed by NKG2D and DAP10.Science,1999,285(5428):730-732.
[51]Diefenbach A, Jensen ER, Jamieson AM, et al.Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature,2001,413(6852):165-171.
[52]Jamieson AM, Diefenbach A, McMahon CW, et al.The role of the NKG2D immunoreceptor in immune cell activation and natural killing.Immunity,2002 17(1):19-29.
[53]Romanski A, Bug G, Becker S,et al.Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol,2005, 33(3):344-352.
[54]Salih HR, Antropius H, Gieseke F, et al.Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood,2003,102 (4):1389-1396.
[55]Carbone E, Neri P, Mesuraca M, et al.HLA class I,NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.Blood,2005,105(1):251-258.
[56]Qi J, Peng P, Dai MH, et al.Cytotoxicity of MICA-reactive V delta 1 gamma delta T cells towards epithelial tumor cells] Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2004,26(1):1-7.
[57]Germain C,Larbouret C,Cesson V,et al.MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.Clin Cancer Res,2005,11(20):7516-7522.
[58]Groh V, Li YQ, Cioca D,et al.Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A,2005,102(18):6461-6466.
[59]Friese MA,Platten M, Lutz SZ,et al.MICA/NKG2D-mediated immunogene therapy of experimental gliomas.Cancer Res,2003,63(24):8996-9006.
[60]Armeanu S,Bitzer M,Lauer UM,et al.Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.Cancer Res,2005,65(14):6321-6329.
[61]Holdenrieder S,Stieber P, Peterfi A, Nagel D,Steinle A, Salih HR. Soluble MICA in malignant diseases.Int J Cancer,2006,118:684-687
[62]Salih HR,Rammensee HG.Steinle A,Down-regulation of MICA on human tumors by proteolytic shedding.J Immunol,2002,169(8):4098-4102.
[63]Kaiser BK, Yim D, Chow IT, et al. Disulphideisomerase-enabled shedding of tumour-associated NKG2D ligands. Nature,2007,447:482-486.
[64]D.Robert Siemens,et al.Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule:Role of Nitric Oxide.Cancer Res,2008,68(12):4746-4753.
[65]丁修敬,陈晓峰,王和勇,等.MHCI类链相关蛋白A在肿瘤免疫中的作用研究.临床肿瘤学杂志,2008,13(6)：566-568.
[66]Marten A, von Lilienfeld-Toal M, Buchler MW, Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer,2006,119(10):2359-2365.
[67]Groh V,Wu J,Yee C,Spies T.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature,2002,419:734-738.
[68]张彩,冯进波,王郡甫,等.膜型／分泌型MICA对NK细胞受体NKG2D的相反调节效应及其对NK细胞受体谱的影响.中华微生物学和免疫学杂志,2004,24：107-111.
[69]Jinushi M, Takehara T, Tatsumi T, et al.Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol,2005,43(6):1013-1020.
[70]Doubrovina ES,Doubrovin MM, Vider E, et al.Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol,2003,171:6891-6899.
[71]Rebmann V, Schutt P, Brandhorst D,et al.Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.Clin Immunol,2007,123(1):114-120.
[2]Lowenfels AB,Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol,2004,34(5):238-244.
[3]Jemal A, Siegel R, Ward E, Cancer statistics,2009. CA Cancer J Clin, 2009,59(4):225-249.
[4]Kleeff J, Michalski C,Friess H,Pancreatic cancer:from bench to 5-year survival. Pancreas,2006,33(2):111-118.
[5]Brasiuniene B,Juozaityte E.The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina (Kaunas), 2007,43(9):716-725.
[6]Ishigami S,Natsugoe S,Tokuda K,et al.Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer,2000,8(3):577-583.
[7]Coca S,Perez-Piqueras J, Martinez D, et al.The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 1997,9(12):2320-2328.
[8]Takanami I,Takeuchi K, Giga M.The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg,2001,21(6):1058-1063.
[9]Smyth MJ, Cretney E, Kelly JM, Activation of NK cell cytotoxicity. Mol Immunol,2005,42(4):501-510.
[10]陈慰峰.医学免疫学.人民卫生出版社.
[11]Cerwenka A, Lanier LL.NKG2D ligands:unconventional MHC class I like molecules exploited by viruses and cancer. Tissue Antigen,2003,61(5):335-343.
[12]Zhang C, Zhang J, Wei H, et al.Immunoreceptor and its ligands [J].Int Immunopharmacol,2005,5(7-8):1099-1111.
[13]Bahram S,Bresnahan M, Geraghty DE,et al.A second lineage of mammalian major histocompatibility complex class I genes.Proc Natl Acad Sci U S A,
1994,91(14):6259-6263.
[14]Ostberg JR, Dayanc BE, Yuan M, et al.Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.J Leukoc Biol,2007,82(5):1322-1331.
[15]Raulet DH.Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol,2003,3(10):781-790.
[16]Molinero LL,Fuertes MB,Rabinovich GA,et al.Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.J Leukoc Biol, 2002,71(5):791-797.
[17]Watson NF,et al.Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.Int J Cancer,2006,18(6):1445-1452.
[18]Madjd Z,Spendlove I,Moss R,et al.Upregulation of MICA on high-grade invasive operable breast carcinoma. Cancer Immun,2007,7(6):17-19.
[19]Clayton A,Tabi Z.Exosomes and the MICA-NKG2D system in cancer.Blood Cells Mol Dis,2005,34(3):206-213.
[20]Fuertes MB,Girart MV, Molinero LL,et al.Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol,2008,180(7): 4606-4014.
[21]Stastny P.Introduction:MICA/MICB in innate immunity, adaptive immunity, autoimmunity,cancer,and in the immune response to transplants.Hum Immunol, 2006,67(3):141-144.
[22]Groh V,Rhinehart R,Secrist H,et al.Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.Proc. Natl.Acad. Sci.U. S.A,1999,96:6879-6884.
[23]Vetter CS,Groh V, thor Straten P, et al.Expression of stress-induced MHC class I related chain molecules on human melanoma.J.Invest.Dermatol,2002,118:600-605.
[24]Jinushi M,Takehara T,Tatsumi T, et al.Expression and role of MICA and MICB
in human hepatocellular carcinomas and their regulation by retinoic acid.Int.J. Cancer,2003,104:354-361.
[25]Bauer S,Groh V,Wu J,et al.Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.Science,1999,285(5428):727-729.
[26]Pardoll DM.Immunology.Stress,NK receptors, and immune surveillance.Science, 2001,294(5542):534-536.
[27]Diefenbach A, Jensen ER, Jamieson AM,et al.Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature,2001,413(6852):165-171.
[28]Groh V,Wu J,Yee C,et a 1.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.Nature,2002,419:734-738.
[29]Holdenrieder S,Stieber P, Peterfi A, et al.Soluble MICA in malignant diseases. Int J Cancer,2006,118:684-687
[30]Kaiser BK,Yim D,Chow IT,et al.Disulphideisomerase-enabled shedding of tumour-associated NKG2D ligands.Nature,2007,447:482-486.
[31]Salih HR,Rammensee HGSteinle A,Down-regulation of MICA on human tumors by proteolytic shedding.J Immunol,2002,169(8):4098-4102.
[32]Palmisano R,Itoh Y.Analysis of MMP-dependent cell migration and invasion. Methods Mol Biol,2010,622:379-392.
[33]Blobel CP. ADAMs:key components in EGFR signalling and development. Nat Rev Mol Cell Biol,2005,6(1):32-43.
[34]Reiss K,Ludwig A.Breaking up the tie:disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther,2006, 111:985-1006.
[35]White JM.ADAMs:modulators of cell-cell and cell-matrix interactions.Curr Opin Cell Biol,2003,15(5):598-606.
[36]Waldhauer I,Goehlsdorf D,Gieseke F, et al.Tumor-Associated MICA Is Shed by ADAM Proteases.Cancer Res,2008,68(15):6368-6376.
[37]Lake RA,Robinson BW.Immunotherapy and chemotherapy--a practical partner-ship.Nat Rev Cancer,2005,5(5):397-405.
[38]Weiskirch LM.Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice
engaged in tumor eradication following low-dose melphalan therapy.Cancer Immunol Immunother,1994,38(4):215-224.
[39]Yuan L,Kobayashi M, Kuramitsu Y,et al.Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor beta in rats bearing KDH-8 hepatoma cells.Cancer Immunol Immunother,1997,45(2):71-76.
[40]Machiels JP, Reilly RT, Emens LA, et al.Cyclophosphamide,doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/ macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.Cancer Res,2001,61(9):3689-3697.
[41]Merritt RE, Mahtabifard A, Yamada RE, et al.Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.J Thorac Cardiovasc Surg,2003,126(5):1609-1617.
[42]Peter Ujhazy, Gintaras Zaleskis, Enrico Mihich.Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother,2003,52(7):463-472.
[43]Jinushi M,Takehara T,Tatsumi T,et al.Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.Int Jcancer,2003,104(3):354-361.
[44]meanu S,Bitzer M,Lauer UM,et al.Natural killer cell mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histonedeacetylase inhibitor sodium valproate.Cancer Res,2005,65(14):6321-6329.
[45]Gasser S,Orsulic S,Brown EJ,et al.The DNA damage pathway regulates innate immune system 1 igands of the NKG2D receptor.Nature,2005,436 (7054):1186-1190.
[46]Suzuki E, Sun J, Kapoor V, et al.Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.Cancer Biol Ther,2007,6(6):880-885
[47]Li K, Mandai M, Hamanishi J, Matsumura N.et al.Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer:high expression of ULBP2 is an indicator of poor prognosis.Cancer Immunol Immunother
2009,58(5):641-652.
[48]Groh V, A.Steinle, S.Bauer, et al.Recognition of stress-induced MHC molecules by intestinal epithelial T cells.Science,1998,279:1737-1740.
[49]Zwirner NW, Dole K, Stastny P. Differential surface expression of MICA by endothelial cells,fibroblasts,keratinocytes,and monocytes.Hum.Immunol,1999, 60:323-330.
[50]Yamamoto K, Fujiyama Y, Andoh A, et al.Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biophys Acta,2001,1526(1):10-12.
[51]Cerwenka A,Lanier LL.NKG2D ligands:unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens,2003,61:335-343
[52]Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K,Plymate SR. Prevalent expression of the immunostimulatoryMHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest,2004,114:560-568.
[53]Angela Marten, Marie von Lilienfeld-Toal,Markus W, et al.Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int. J.Cancer,2006,119:2359-2365.
[54]Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases.Int J Cancer,2006,118(3):684-687.
[55]Kohga K, Takehara T, Tatsumi T, et al.Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci,2008,99(8):1643-1649.
[56]Kim S,Iizuka K,Aguila HL, Weissman IL, et al.In vivo natural killer cell activities revealed by natural killer cell-deficient mice.Proc Natl Acad Sci U S A,2000,97(6):2731-2736.
[57]Pross HF,Lotzova E.Role of natural killer cells in cancer.Nat Immunol,1993,12(4-5):279-292.
[58]Aparicio-Pages MN,Verspaget HW, Pena AS,et al.Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract.J Clin Lab Immunol,1991,35(1):27-32.
[59]Cosman D,Mullberg J,Sutherland CL,et al.ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity,2001,14(2):123-133.
[60]Busche A, Goldmann T, Naumann U,et al.Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther,2006,17 (2):135-146.
[61]Friese MA, Platten M, Lutz SZ, et al.MICA/NKG2D-mediated immunogene therapy of experimental gliomas.Cancer Res,2003,63(24):8996-9006.
[62]Smyth MJ, Godfrey DI,Trapani JA.A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol,2001,2(4):293-299.
[63]Angela Marten,Marie von Lilienfeld-Toal,Markus W, et al.Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int.J. Cancer,2006,119:2359-2365.
[64]Doubrovina ES, Doubrovin MM, Vider E, et al.Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.J Immunol,2003,171:6891-6899.
[65]Shun-Yao Ko,Shu-Chun Lin, Yong-Kie Wong,et al.Increase of disintergin metalloprotease 10 (ADAM 10) expression in oral squamous cell carcinoma. Can-cer Letters.2007;245(1-2):33-43.
[66]Mochizuki S,Okada Y.ADAMs in cancer cell proliferation and progression. Cancer Sci,2007,98(5):621-628.
[67]Huovila AP, Turner AJ, Pelto-Huikko M,et al.Shedding light on ADAM metalloproteinases.Trends Biochem Sc,2005,30(7):413-422.
[68]Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response:implications for combination chemo-immunotherapy. Cancer Res,2002,62(8):2353-2358.
[69]Nowak AK, Lake RA,Marzo AL,et al.Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.J Immunol,2003,170(10):4905-4913.
[70]Le HK, Graham L,Cha E.Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.Int Immunopharmacol, 2009,9(7-8):900-909.
[71]Bang S,Kim HS,Choo YS,et al.Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas,2006,32(1):29-36.
[72]Hirooka Y, Itoh AKawashima H,et al.A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas,2009,38(3):69-74
[73]Correale P, Cusi MG, Tsang KY,et al.Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.J Clin Oncol,2005,23(35):8950-8958.
[74]Dudley ME, Wunderlich JR, Yang JC,et al.Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005,23(10):2346-2357.
[1]Bhram S,Bresnahan M,Geraghty DE,et al.A second lineage of mammnalian major histocompatibility complex class I genes.Proc Natl Acad Sci USA,1994,91 (14):6259-6263.
[2]Bhram S,Mizuki N,Inoko H,et al.Nucleotide sequence of the human MHC class I MICA gene.Immunogenetics,1996,44(1):80-81.
[3]Perez-Rodriguez M,Arguello JR,Fischer G,et al.Further polymorphism of the MICA gene.Eur J Immunogenet,2002,29(l):35-46.
[4]Li P,Morris DL,Willcox BE,Steinle A,Spies T,Strong RK.Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA.Nat Immunol,2001,2(5):443-451.
[5]Perez-Rodriguez M, Arguello JR, Fischer G,et al.Further polymorphism of the MICA gene.Eur J Immunogenet,2002,29(1):35-46.
[6]Fodil N, Laloux L,Wanner V,et al.Allelic repertoire of the human MHC class Ⅰ MICA gene.Immunogenetics,1996,44(5):351-357.
[7]Suemizu H,Radosavljevic M, Kimura M,et al.A basolateral sorting motif in the MICA cytoplasmic tail.Proc Natl Acad Sci U S A,2002,99(5):2971-2976.
[8]Lengyel CS,Willis LJ, Mann P,et al.Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity. J Biol Chem,2007,282(42):30658-30666.
[9]Petersdorf EW, Shuler KB,Longton GM,et al.Population study of allelic
diversity in the human MHC class I-related MIC-A gene.Immunogenetics,1999, 49(7-8):605-612.
[10]Katsuyama Y, Ota M,Ando H,et al.Sequencing based typing for genetic polymorphisms in exons,2,3 and 4 of the MICA gene.Tissue Antigens,1999,54 (2):178-184.
[11]龚卫娟,范丽安,杨珏琴,等.三个群体MICA基因外显子2、3和4的多态性研究.中华医学遗传学杂志,2002,19(4)：336-339.
[12]Ribas F.Olivera LA,Petzl-Erler ML,et al.Major histocompatib-ility complex class I chain-related gene A polymorphism and linkage disequilibrium with HLA-B alleles in Euro-Brazilians.Tissue Antigens,2008,72(6):532-538.
[13]Lucas D,Campillo JA,L6pez-Hernandez R, et al.Allelic diversity of MICA gene and MICA/HLA-B haplotypic variation in a population of the Murcia region in southeastern Spain.Hum Immunol,2008,69(10):655-660.
[14]Yabuki K, Ota M,Goto K, Kimura T,et al.Triplet repeat polymorphism in the MICA gene in HLA-B27 positive and negative caucasian patients with ankylosing spondylitis.Hum Immunol,1999,60(1):83-86.
[15]肖翠英,张思仲,程璐,等.中国四个人群中MICA基因多态性研究.中华医学遗传学杂志,2000,17(6)：424-428.
[16]Lo SS,Lee YJ, Wu CW,et al.The increase of MICA gene A9 allele associated with gastric cancer and less schirrous change.Br J Cancer,2004,90(9):1809-13.
[17]Chung-Ji L,Yann-Jinn L,Hsin-Fu L,et al.The increase in the frequency of MICA gene A6 allele in oral squamous cell carcinoma. J Oral Pathol Med,2002,31(6): 323-328.
[18]Liu CJ,Lee YJ, Chang KW,et al.Polymorphism of the MICA gene and risk for oral submucous fibrosis.J Oral Pathol Med,2004,33(1):1-6.
[19]Tamaki S,Sanefuzi N, Ohgi K,et al.An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinoma in Japanese patients.J Oral Pathol Med,2007,36(6):351-356.
[20]Tian W,Zeng XM, Li LX,et al.Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population.Immunogenetics,2006,58(2-3):113-121.
[21]Kennedy C, Naipal A, Gruis NA,et al.MICA gene polymorphism is not associated with an increased risk for skin cancer. J Invest Dermatol,2002,118(4): 686-691.
[22]Lavado-Valenzuela R,Benavides. M,Carabantes F, MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer. Tissue Antigens,2009,74(1):46-49.
[23]Ostberg JR,Dayanc BE,Yuan M,et al.Enhancement of natural killer(NK) cell Cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.J Leukoc Biol,2007,82(5):1322-1331.
[24]Raulet DH.Roles of the NKG2D imunoreceptor and its ligands.Nat Rev Immunol,2003,3(10):781-790.
[25]Molinero LL,Fuertes MB,Rabinovich GA,et al.Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.J Leukoc Biol,2002,71(5):791-797.
[26]Hankey KQDrachenberg CB,Papadimitriou JC,et al.MIC expression in renal and pancreatic allografts.Transplantation,2002,73(2):304-306.
[27]Kato M,Kinukawa T,Hattori R,et al.Does MICA influence acute rejection in kidney transplantation.Clin Transpl,2006,389-393.
[28]Morales-Buenrostro LE,Rodrfguez-Romo R,de Leo C,et al.HLA and MICA antibodies:further evidence of their impact on graft loss two years after their detection.Clin Transpl,2006,207-218.
[29]Watson NF,Spendlove I,Madjd Z,et al.Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.Int J Cancer,2006,118(6):1445-1452.
[30]Clayton A,Tabi Z.Exosomes and the MICA-NKG2D system in cancer.Blood Cells Mol Dis,2005,34(3):206-213.
[31]Madjd Z,Spendlove I,Moss R,et al.Upregulat ion of MICA on high-grade invasive operable breast carcinoma.Cancer Immun,2007,7:17.
[32]Fuertes MB,Girart MV,Molinero LL,et al.Intracellular Retention of the NKG2D 1 igand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.J Immunol,2008, 180(7):4606-4614.
[33]Stastny P.Introduction:MICA/MICB in innate immunity,adaptive immunity, autoimmunity,cancer,and in the immune response to transplants.Hum Immunol,2006,67(3):141-144.
[34]Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer,2006,119(10):2359-2365.
[35]Groh V, et al.Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB.Proc.Natl.Acad.Sci.U. S.A,1999,96:6879-6884.
[36]Jinushi M,Takehara T,Tatsumi T.et al.Autocrine/paracrineIL-15 that is required fortype I IFN-mediated dendritic eel l expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection.J Immunol,2003,171(10): 5423-5429.
[37]Zhang C,Zhang J,Sun R,et al.Opposing effect of IFN-gamma and IFN-alpha on expression of NKG2 receptors:negative regulation of IFN-gamma on NK cells.Int Immunopharmacol,2005,5(6):1057-1067.
[38]Friese MA,Wischhusen J,Wick W,et al.RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response,inhibits glioma cell migration and invasiveness,and abrogates tumorigenicity in vivo.Cancer Res,2004,64(20):7596-7603.
[39]Eisele G,Wischhusen J,Mittelbronn M,et al.TGF-beta and metalloproteinases differenially suppress NKG2D ligand surface expression on malignant glioma cells Brain,2006,129(Pt 9):2416-25.
[40]Molinero LL,Fuertes MB,Girart Mv,et al.NF-K B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes.J Immunol,2004, 173(9):5583-5590.
[41]Jinushi M,Takehara T,Tatsumi T,et al.Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid.Int Jcancer,2003,104(3):354-361.
[42]meanu S,Bitzer M,Lauer UM,et al.Natural killer cell mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histonedeacetylase inhibitor sodium valproate.Cancer Res.2005;65(14):6321-6329.
[43]Gasser S,Orsulic S,Brown EJ,et al.The DNA damage pathway regulates innate immune system 1 igands of the NKG2D receptor.Nature,2005;436 (7054):1186-1190.
[44]Zou Y,Bresnahan W,Taylor RT,et al.Effect of human cytomegalovirus on expression of MHC class I-related chains A.J Immunol,2005,174(5):3098-4004.
[45]Friese MA,Wischhusen J, Wick W,et al.RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness,and abrogates tumorigenicity in vivo.Cancer Res,2004,64(20):7596-7603.
[46]Bauer S,Groh V, Wu J,et al.Activation of NK cells and T cells by NKG2D,a receptor for stress-inducible MICA.Science,1999,285(5428):727-729.
[47]Pardoll DM.Immunology. Stress, NK receptors, and immune surveillance. Science,2001,294(5542):534-536.
[48]Diefenbach A, Tomasello E, Lucas M,et al.Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D.Nat Immunol,2002,3(12):1142-1149.
[49]Long EO. Versatile signaling through NKG2D.Nat Immunol,2002,3(12): 1119-1120
[50]Wu J, Song Y, Bakker AB,et al.An activating immunoreceptor complex formed by NKG2D and DAP10.Science,1999,285(5428):730-732.
[51]Diefenbach A, Jensen ER, Jamieson AM, et al.Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature,2001,413(6852):165-171.
[52]Jamieson AM, Diefenbach A, McMahon CW, et al.The role of the NKG2D immunoreceptor in immune cell activation and natural killing.Immunity,2002 17(1):19-29.
[53]Romanski A, Bug G, Becker S,et al.Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol,2005, 33(3):344-352.
[54]Salih HR, Antropius H, Gieseke F, et al.Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood,2003,102 (4):1389-1396.
[55]Carbone E, Neri P, Mesuraca M, et al.HLA class I,NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.Blood,2005,105(1):251-258.
[56]Qi J, Peng P, Dai MH, et al.Cytotoxicity of MICA-reactive V delta 1 gamma delta T cells towards epithelial tumor cells] Zhongguo Yi Xue Ke Xue Yuan Xue Bao,2004,26(1):1-7.
[57]Germain C,Larbouret C,Cesson V,et al.MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.Clin Cancer Res,2005,11(20):7516-7522.
[58]Groh V, Li YQ, Cioca D,et al.Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A,2005,102(18):6461-6466.
[59]Friese MA,Platten M, Lutz SZ,et al.MICA/NKG2D-mediated immunogene therapy of experimental gliomas.Cancer Res,2003,63(24):8996-9006.
[60]Armeanu S,Bitzer M,Lauer UM,et al.Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.Cancer Res,2005,65(14):6321-6329.
[61]Holdenrieder S,Stieber P, Peterfi A, Nagel D,Steinle A, Salih HR. Soluble MICA in malignant diseases.Int J Cancer,2006,118:684-687
[62]Salih HR,Rammensee HG.Steinle A,Down-regulation of MICA on human tumors by proteolytic shedding.J Immunol,2002,169(8):4098-4102.
[63]Kaiser BK, Yim D, Chow IT, et al. Disulphideisomerase-enabled shedding of tumour-associated NKG2D ligands. Nature,2007,447:482-486.
[64]D.Robert Siemens,et al.Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule:Role of Nitric Oxide.Cancer Res,2008,68(12):4746-4753.
[65]丁修敬,陈晓峰,王和勇,等.MHCI类链相关蛋白A在肿瘤免疫中的作用研究.临床肿瘤学杂志,2008,13(6)：566-568.
[66]Marten A, von Lilienfeld-Toal M, Buchler MW, Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer,2006,119(10):2359-2365.
[67]Groh V,Wu J,Yee C,Spies T.Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature,2002,419:734-738.
[68]张彩,冯进波,王郡甫,等.膜型／分泌型MICA对NK细胞受体NKG2D的相反调节效应及其对NK细胞受体谱的影响.中华微生物学和免疫学杂志,2004,24：107-111.
[69]Jinushi M, Takehara T, Tatsumi T, et al.Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol,2005,43(6):1013-1020.
[70]Doubrovina ES,Doubrovin MM, Vider E, et al.Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol,2003,171:6891-6899.
[71]Rebmann V, Schutt P, Brandhorst D,et al.Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.Clin Immunol,2007,123(1):114-120.